Beta-adrenergic blocking agents in the treatment of congestive heart failure: Mechanisms and clinical results

Annual Review of Medicine

Volumn 48, Issue , 1997, Pages 103-114

  Doughty, Robert Neil ^a   Sharpe, Norman ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Beta blockers; Clinical trials; Heart failure; Prognosis

Indexed keywords

ACEBUTOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; LABETALOL; METOPROLOL; NEBIVOLOL;

ADRENERGIC SYSTEM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG MECHANISM; EXERCISE TOLERANCE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; EXERCISE TEST; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR FUNCTION, LEFT;

EID: 0031051206     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.48.1.103     Document Type: Review

References (70)

1. Smith WM. 1985. Epidemiology of congestive heart failure. Am. J. Cardiol. 55: 3-8A
2. The CONSENSUS Trial Study Group. 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enal april Survival Study (CONSENSUS). N. Engl. J. Med. 316:1429-35
3. The SOLVD Investigators. 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325:293-302
4. Pfeffer MA, Braunwald E, Moye LA, et al. 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N. Engl J. Med. 327: 669-77
5. Waagstein F, Hjalmarson A, Varnauskas E, et al. 1975. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br. Heart. J. 37:1022-36
6. Swedberg K, Hjalmarson A, Waagstein F, et al. 1979. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1:1374-77
7. Swedberg K, Hjalmarson A, Waagstein F, et al. 1980. Beneficial effects of long term beta-blockade in congestive cardiomyopathy. Br. Heart. J. 44:117-33
8. Doughty RN, MacMahon S, Sharpe N. 1994. Beta-blockers in heart failure: promising or proved? J. Am. Coll. Cardiol. 23: 814-21
9. Ikram H, Fitzpatrick D. 1981. Double-blind trial of chronic oral beta-blockade in congestive cardiomyopathy. Lancet 2:490-93
10. Currie PJ, Kelly MJ, McKenzie A, et al. 1984. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J. Am. Coll. Cardiol. 3:203-9
11. Anderson JL, Lutz JR, Gilbert EM, et al. 1985. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am. J. Cardiol. 55:471-75
12. Engelmeier RS, O Connell JB, Walsh R, et al. 1985. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 72:536-46
13. Sano H, Kawabata N, Yonezawa K, et al. 1989. Metoprolol was more effective than captopril for dilated cardiomyopathy in Japanese patients. Circulation 80(Suppl. II):118 (Abstr.)
14. Leung W, Lau C, Wong C, et al. 1990. A double-blind cross-over trial of labetalol in patients with dilated cardiomyopathy. Am. Heart J. 119:884-90
15. Pollock SG, Lystash J, Tedesco C, et al. 1990. Usefulness of bucindolol in congestive heart failure. Am. J. Cardiol. 66:603-7
16. Gilbert EM, Anderson JL, Deitchman D, et al. 1990. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am. J. Med. 88:223-29
17. Woodley SL, Gilbert EM, Anderson JL, et al. 1991. Beta-blockade with bucindolol in heart failure caused by ischaemic versus idiopathic dilated cardiomyopathy. Circulation 84:2426-41
18. Paolisso G, Gambardella A, Marrazzo G, et al. 1992. Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure. Am. Heart J. 123:1397-404
19. Waagstein F, Bristow MR, Swedberg K, et al. 1993. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441-46
20. Wisenbaugh T, Katz I, Davis J, et al. 1993. Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J. Am. Coll. Cardiol. 21:1094-100
21. Fisher ML, Gottlieb SS, Plotrick GD, et al. 1994. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J. Am. Coll. Cardiol. 23:943-50
22. Bristow MR, O Connell JB, Gilbert EM, et al. 1994. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischaemic cardiomyopathy. Circulation 89:1632-42
23. Eichhorn EJ, Heejch CM, Barnet JH, et al. 1994. Effect of metoprolol on myocardial function and energetics in patients with non-ischaemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 24: 1310-20
24. CIBIS Investigators. 1994. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation 90:1765-73
25. Metra M, Nardi M, Giubbini R, et al. 1994. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 24:1678-87
26. Olsen SL, Gilbert EM, Renlund DG, et al. 1995. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J. Am. Coll. Cardiol. 25:1225-31
27. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. 1995. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 92:1499-506
28. Australia-New Zealand Heart Failure Research Collaborative Group. 1995. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischaemic heart disease. Circulation 92: 212-18
29. Packer M, Bristow M, Cohn J. et al. 1995. Effect of carvedilol on the survival of patients with chronic heart failure. Circulation 92(Suppl. I):142 (Abstr.)
30. Packer M. 1992. The neurohormonal hypothesis: a theory to explain the mechanisms of disease progression in heart failure. J. Am. Coll. Cardiol. 20:248-54
31. Thomas JA, Marks BH. 1978. Plasma norepinephrine in congestive heart failure. Am. J. Cardiol. 41:233-43
32. Cohn JN, Levine B, Olivari MT, et al. 1984. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311:819-23
33. Cohn JN, Simon A, Johnson G, et al. 1991. Relationship of plasma norepinephrine and plasma renin activity to mortality in heart failure: V-HeFT II. Circulation 84(Suppl. II):310 (Abstr.)
34. Francis GS, Benedict C, Johnstone DE, et al. 1990. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82:1724-29
35. Hasking GJ, Esler MD, Jennings GL, et al. 1986. Norepinephrine spillover in plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73:615-21
36. Kaye DM, Lefkovits J, Jennings G, et al. 1995. Adverse consequences of high sympathetic nervous activity in the failing human heart. J. Am. Coll. Cardiol. 26: 1257-63
37. Szakacs JE, Cannon A. 1958. Norepinephrine myocarditis. Am. J. Clin. Pathol. 30:425-35
38. Bigger JT. 1987. Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. Circulation 75(Suppl. IV):28-35
39. Mancia G. 1990. Sympathetic activation in congestive heart failure. Eur. Heart. J. 11(Suppl. A):3-11
40. Meredith IT, Eisenhofer G, Lambert GW, et al. 1993. Cardiac sympathetic activity in congestive heart failure: evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 88:615-21
41. Chidsey CA, Braunwald E, Morrow AG. 1965. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am. J. Med. 39:442-51
42. 1-receptor down-regulation in heart failure. Circ. Res. 59: 297-309
43. 2-adrenergic receptor-mediated adenylate cyclase stimulation in non-failing and failing human ventricular myocardium. Mol. Pharmacol. 35: 295-303
44. Bristow MR, Hershberger RE, Port JD, et al. 1990. Beta-adrenergic pathways in non-failing and failing human ventricular myocardium. Circulation 82(Suppl. I):12-25
45. Imperato-McGinley J, Gautier T, Ehlers K, et al. 1987. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma. N. Engl. J. Med. 316:793-97
46. Cruickshank JM, Neil-Dwyer G, Degaute JP, et al. 1987. Reduction of stress/catecholamine-induced cardiac necrosis by beta1-selective blockade. Lancet 1:585-89
47. Bristow MR, Gilbert EM, Olsen S, et al. 1993. Long-term metoprolol therapy increases myocardial beta-adrenergic receptor density relative to placebo controls. J. Am. Coll. Cardiol. 21(Suppl. A):101 (Abstr.)
48. 2-adrenoceptor changes following chronic beta-adrenoceptor antagonism. Eur. J. Clin. Pharmacol 32:237-43
49. Bigger JT, Coromilas J. 1984. How do beta-blockers protect after myocardial infarction? Ann. Intern. Med. 101:256-58
50. Weksler BB, Gillick M, Pink J. 1977. Effects of propranolol on platelet function. Blood 49:185-96
51. Frishman WH, Lazar EJ. 1990. Reduction of mortality, sudden death and non-fatal re-infarction with beta-adrenergic blockers in survivors of acute myocardial infarction: a new hypothesis regarding the cardioprotective action of beta-adrenergic blockade. Am. J. Cardiol. 66:66-70G
52. Sharpe N, MacMahon S. 1995. Effects of 12 months treatment with carvedilol on left ventricular function and exercise performance in patients with heart failure of ischaemic aetiology. Circulation 92(Suppl. I):394 (Abstr.)
53. Sweeney ME, Fletcher BJ, Fletcher GF. 1989. Exercise testing and training with beta-adrenergic blockade: role of drug washout period in unmasking a training effect. Am. Heart J. 118:941-46
54. Lipkin DP, Scriven AJ, Crake T, et al. 1986. Six minute walking test for assessing exercise capacity in chronic heart failure. Br. Med. J. 292:653-55
55. Franciosa JA, Park M, Levine TB. 1981. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am. J. Cardiol. 47:33-39
56. Clark A, Coats A. 1994. Mechanisms of exercise intolerance in cardiac failure: abnormalities of skeletal muscle and pulmonary function. Curr. Opin. Cardiol. 9: 305-14
57. Drexler H. 1995. Changes in the peripheral circulation in heart failure. Curr. Opin. Cardiol. 10:268-73
58. Bristow MR, Gilbert EM, Abraham WT, et al. 1995. Multicenter oral carvedilol heart failure assessment (MOCHA): a six-month dose-response evaluation in class II-IV patients. Circulation 92(Suppl. I):142 (Abstr.)
59. Packer M, Colucci WS, Sackner-Bernstein JD, et al. 1995. Prospective randomized evaluation of carvedilol on symptoms and exercise tolerance in chronic heart failure: results of the PRECISE trial. Circulation 92(Suppl. I):143 (Abstr.)
60. Cohn J, Fowler MB, Bristow MA, et al. 1996. Effect of carvedilol in severe chronic heart failure. J. Am. Coll. Cardiol. 27(Suppl. A):169 (Abstr.)
61. Colucci WS, Packer M, Bristow MR, et al. 1995. Carvedilol inhibits clinical progression in patients with mild heart failure. Circulation 92(Suppl. I):395 (Abstr.)
62. The BEST Steering Committee. 1995. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am. J. Cardiol. 75: 1220-23
63. Erbel R, Schweizer P, Krebs W, et al. 1984. Effects of heart rate changes on LV volume and ejection fraction: a 2-dimensional echocardiographic study. Am. J. Cardiol. 53:590-97
64. Ikram H, Chan W, Bennett SI, et al. 1979. Haemodynamic effects of acute beta-adrenergic receptor blockade in congestive cardiomyopathy. Br. Heart. J. 42:311-15
65. Hall SA, Cigarroa CG, Marcoux L, et al. 1995. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J. Am. Coll. Cardiol. 25:1154-61
66. Andersson B, Hamm C, Persson S, et al. 1993. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blocker treatment. J. Am. Coll. Cardiol. 23:1397-404
67. Eichhorn EJ, Bedotto JB, Malloy CR, et al. 1990. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile and diastolic performance with bucindolol. Circulation 82:473-83
68. Fowler MB, Gilbert M, Cohn JN, et al. 1996. Effects of carvedilol on cardiovascular hospitalizations in patients with chronic heart failure. J. Am. Coll. Cardiol. 27(Suppl. A):169 (Abstr.)
69. McMurray J, Hart W. 1993. The economic impact of heart failure on the National Health Service. Br. Heart. J. 69(Suppl.):19 (Abstr.)
70. Feuerstein GZ, Poste G, Ruffolo RR. 1995. Carvedilol update III: rationale for use in congestive heart failure. Drugs Today 31(Suppl. F):1-23